RadNet To Participate in the White House Cancer Moonshot Goals Forum
RadNet, Inc. (NASDAQ: RDNT) announced that CEO Howard Berger will participate in the Cancer Moonshot Goals Forum, aimed at reducing cancer mortality by 50% over 25 years. The White House has invited RadNet, a leader in outpatient diagnostic imaging, to leverage its expertise in cancer screening and artificial intelligence. Currently performing 5% of mammograms nationally, RadNet plans to expand its AI-driven tools for detecting other cancers. Dr. Berger emphasized the importance of early detection for improving cancer outcomes and called for collaboration to drive substantial changes in care.
- None.
- None.
LOS ANGELES, May 11, 2022 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), today announced that Howard Berger, M.D., the company’s President and Chief Executive Officer, will participate this week in the Cancer Moonshot Goals Forum, a consortium of healthcare leaders invited by the White House to strategize on ways to accelerate progress against cancer. RadNet is a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 351 owned and operated outpatient imaging centers across the U.S.
The White House has called for private sector commitments to achieve the goal of the Cancer Moonshot, a
“Currently, we perform approximately five percent of all mammograms nationwide and we expect this number to grow in the future,” said Dr. Berger. “While AI is dramatically improving our detection capability, efficiency and overall accuracy with respect to breast cancer, we are also developing tools utilizing similar AI and machine learning technologies for the other most prevalent cancers, including prostate, lung and colon. If the healthcare delivery system were to promote similar screening programs to mammography for these other types of cancers, we believe the impact on cancer mortality would be substantial.”
Diagnostic imaging is a critical component in the fight against cancer and is the gateway to population health. Cancer screening powered by AI is a solution that RadNet is already applying to meet the country's call to action in the fight against cancer. “Screening and early detection are proven to improve cancer mortality rates,” Dr. Berger noted. “We welcome this opportunity to collaborate with other providers, government entities, non-profits and caregivers so that we can initiate meaningful changes in patients’ lives.”
About RadNet, Inc.
RadNet, Inc., is the leading national provider of freestanding, fixed-site diagnostic imaging services and related information technology solutions (including artificial intelligence) in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 351 owned and/or operated outpatient imaging centers. RadNet's markets include Arizona, California, Delaware, Florida, Maryland, New Jersey and New York. Together with affiliated radiologists, inclusive of full-time and per diem employees and technicians, RadNet has a total of approximately 9,000 employees. For more information, visit http://www.radnet.com.
CONTACT:
RadNet, Inc.
Mark Stolper
Executive Vice President and Chief Financial Officer
310-445-2800
FAQ
What is the purpose of RadNet's participation in the Cancer Moonshot Goals Forum?
What percentage of mammograms does RadNet currently perform?
How is RadNet using artificial intelligence in cancer screening?
What other cancers is RadNet developing AI tools for?
How many outpatient imaging centers does RadNet operate?
